Liftstream is an executive search recruitment company in the life sciences sector
UK Government names biotech veteran Minister for Life Sciences
Authored by James Sheppard
Posted in Executive Appointments, M&A Finance and Funding, Pharmaceutical business
Tagged AbbVie, AstraZeneca, Britain, George Freeman, London Biotech, medical research, Merlin Biosciences, Minister for Life Sciences, NHS, One Nucleus, Oxford Biotech, Pfizer, Shire, Stevenage Biotech, Takeda, UK, UK government
Leave a comment
Seattle Genetics strike another alliance deal with Bayer
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADCETRIS, ADCs, alliance, Antibody-drug conjugates, ASCO, Bayer, FDA, Immunogen, innovator, Kadcyla, Lymphoma, oncology, pharmaceutical, Roche, seattle genetics, Takeda
Leave a comment
Aegerion and NPS Pharmaceuticals begin rare disease product launches
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Aegerion Pharma, CHMP positive opinion, commercial opportunities, commercialisation, Dan Rader, Dick Gregg, EMA, europe, Gattex, HoFH, Juxtapid, LOJUXTA, novel therapies, NPS pharma, orphan designation, Orphan drugs, Rare Disease, Revestive, short bowel syndrome, Takeda, USA
Leave a comment
Seattle Genetics delivers more ammunition for ADCs in cancer fight
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged ADCETRIS, ADCs, anaplastic large cell lymphoma, anti-CD30, Antibody-drug conjugates, ASCO, CD30-expressing tumour cells, Hodgkin Lymphoma, mature T-cell lymphoma, monoclonal antibody, MTCL, seattle genetics, Takeda
Leave a comment
Immunomedics updates on its clinical progress with ADC programmes
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged 90Y-clivatuzumab tetraxetan, ADC, antibody drug conjugate, antibodys, autoimmune disease, cancer, clinical development, Clivatuzumab, Cynthia Sullivan, Epratuzumab, gemcitabine, Immunomedics, NHL, oncology, Pancreatic Cancer, Takeda, UCB, Veltuzumab
Leave a comment
Celgene Rides Wave of Growth with Tsunami of Positive News
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abraxane, Abraxis Bioscience, ADC, Antibody-drug conjugates, Apremilast, ASCO-Gastro, Bechets Disease, Bispecifics, Bob Hugin, celgene, CEO, china, Deutsche Bank, EMA, ESTEEM, FDA, Liftstream, Lymphoma, Millennium Pharmaceuticals, PALACE-1, Pomalyst, Revlimid, Takeda, Velcade, Vidaza
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment
NPS Pharmaceuticals gets ready to launch gastro orphan drug
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged commercial, endocrinology, europe, FDA, gastroenterology, Gattex, hormone, Market Access, marketing, Natpara, NPS Pharmaceuticals, Nycomed, Orphan Drug, patients, pricing and reimbursement, Revestive, short bowel syndrome, Takeda, teduglutide, ultra-rare diseases, USA
Leave a comment